The objective of this retrospective study is to investigate laryngeal preservation and long−term treatment results in hypopharyngeal carcinoma treated with intensity−modulated radiotherapy (IMRT) combined with chemotherapy.

Twenty−seven patients with hypopharyngeal carcinoma (stage II−IV) were enrolled and underwent concurrent chemoradiotherapy. The chemotherapy regimens were monthly cisplatin and 5−fluorouracil for 6 patients and weekly cisplatin for 19 patients. All patients were treated with IMRT with simultaneous integrated boost technique. Acute and late toxicities were recorded based on CTCAE 3.0 (Common Terminology Criteria for Adverse Events).

The median follow−up time for survivors was 53.0 months (range 36−82 months). The initial complete response rate was 85.2%, with a laryngeal preservation rate of 63.0%. The 5−year functional laryngeal, local−regional control, disease−free and overall survival rates were 59.7%, 63.3%, 51.0% and 34.8%, respectively. The most common greater than or equal to grade 3 acute and late effects were dysphagia (63.0%, 17 of 27 patients) and laryngeal stricture (18.5%, 5 of 27 patients), respectively. Patients belonging to the high risk group showed significantly higher risk of tracheostomy compared to the low risk group (p=0.014).

After long−term follow−up, our results confirmed that patients with hypopharyngeal carcinoma treated with IMRT concurrent with platinum−based chemotherapy attain high functional laryngeal and local−regional control survival rates. However, the late effect of laryngeal stricture remains a problem, particularly for high risk group patients.

The complete article is available as a provisional PDF. The fully formatted PDF and HTML versions are in production.